HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
Símbolo de cotizaciónHSCS
Nombre de la empresaHeartSciences Inc
Fecha de salida a bolsaJun 15, 2022
Director ejecutivoMr. Andrew Simpson
Número de empleados15
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 15
Dirección550 Reserve St, Suite 360
CiudadSOUTHLAKE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal76092
Teléfono16822377781
Sitio Webhttps://heartsciences.com/
Símbolo de cotizaciónHSCS
Fecha de salida a bolsaJun 15, 2022
Director ejecutivoMr. Andrew Simpson
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos